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An Mll±AF9 Fusion Gene Made by Homologous
Recombination Causes Acute Leukemia in Chimeric
Mice: A Method to Create Fusion Oncogenes
Javier Corral,* Isabelle Lavenir, Helen Impey, the int-2 gene (Mansour et al., 1990). An analogous ho-
Alan J. Warren, Alan Forster, Teresa A. Larson, mologous recombination strategy could therefore be
Sarah Bell,² Andrew N. J. McKenzie, Gareth King, utilized to mimic the consequence of chromosomal
and Terence H. Rabbitts translocations by fusion of coding sequences into an
Medical Research Council Laboratory of Molecular endogenous gene. Thus, in-frame fusion of sequences
Biology with the endogenous gene in embryonal stem (ES) cells
Hills Road would create a fusion gene that utilizes the endogenous
Cambridge CB2 2QH promoter to control expression, as would occur follow-
United Kingdom ing chromosomal translocation.
The human chromosome 11, band q23, is associated
with a remarkable spectrum of different chromosomal
Summary abnormalities, both translocations and inversions (re-
viewed by Bernard and Berger, 1995). This chromosome
Homologous recombination in embryonal stem cells band is involved in over 20% of acute leukemias, and
has been used to produce a fusion oncogene, there- there are more than 25 different chromosomal transloca-
by mimicking chromosomal translocations that fre- tions affecting this region in different leukemias. The
quently result in formation of tumor-specific fusion cloning of the 11q23 breakpoint region (Ziemin-van der
oncogenes in human malignancies. AF9 sequences Poel et al., 1991) revealed a gene, called MLL, ALL-1,
were fused into the mouse Mll gene so that expression or HRX, encoding a large and complex protein (Djabali
of the Mll±AF9 fusion gene occurred from endogenous et al., 1992; Gu et al., 1992; Tkachuk et al., 1992; Domer
Mll transcription control elements, as in t(9;11) found et al., 1993) in which the translocation breakpoints are
in human leukemias. Chimeric mice carrying the fusion clustered in a region around exon 8 (Djabali et al., 1992;
gene developed tumors, which were restricted to Gu et al., 1992; Tkachuk et al., 1992; Corral et al., 1993;
acute myeloid leukemias despite the widespread ac- Domer et al., 1993; Lo-Coco et al., 1993).
tivity of the Mll promoter. Onset of perceptible disease
Various genes are fused to MLL in thedifferent translo-
was preceded by expansion of ES cell derivatives in
cations, yielding fusion proteins in which a similar
peripheral blood. This novel use of homologous re-
N-terminal portion of MLL is fused to a partner protein.combination formally proves that chromosomal trans-
In addition, the subtype of leukemia correlates with thelocations contribute to malignancy and provides a
11q23 abnormality and, therefore, with specific MLL fu-general strategy to create fusion oncogenes for study-
sion proteins. For example, the translocation t(4;11)ing their role in tumorigenesis.
(q21;q23), which generates theMLL±AF4 fusion, is found
predominantly in acute lymphoblastic leukemias (DjabaliIntroduction
et al., 1992; Gu et al., 1992; Domer et al., 1993; Morrissey
et al., 1993; Nakamura et al., 1993), suggesting that theFusion proteins are commonly the result of chromo-
AF4 segment has a role in controlling of the lineage. Thesomal translocations in leukemias and solid tumors in
translocation t(9;11)(p22;q23) is mainly associated withwhich chromosomal breaks occur within genes on each
acute myeloid leukemias and fuses AF9 to MLL (Iida etchromosome (Rabbitts, 1994). In assessing the rele-
vance of such proteins in tumorigenesis, in vivo experi- al., 1993; Nakamura et al., 1993), suggesting a role for
mental models are needed that facilitate the study of AF9 in myeloid disease. Nonetheless, the translocations
tumor development and progression and overt tumor affecting MLL can occur before lineage commitment
outgrowth. Transgenesis is an important method that because different tumor types can carry chromosomes
allows various stages of tumor development to be stud- with similar breakpoints (Corral et al., 1993; Lo-Coco et
ied (Adams and Cory, 1991). However, it has drawbacks, al., 1993; Thirman et al., 1993) and thus the fusion part-
principally the difficulty of choosing a promoter to engi- ners may perform different functions. To define the func-
neer expression in the appropriate cell type in vivo. Ho- tion of the fusion proteins, itwill be necessary to develop
mologous recombination provides an alternative for the a biological model of leukemia associated with MLL
manipulation of genes in the mouse genome (Thomas gene fusions
and Capecchi, 1987). In addition to gene targeting to We have determined the validity of the homologous
produce null mutations, this method can be used to recombination strategy by studying the role of the MLL±
introduce new genetic information into gene loci, for AF9 fusion in tumorigenesis. Homologous recombina-
example, replacement of En-1 by En-2 sequences to tion in ES cells has been used to create an in-frame
rescue the En-1 mutant phenotype (Hanks et al., 1995) fusion of AF9 with exon 8 of mouse Mll. Mutant ES cells
or the introduction of the lacZ gene as a fusion within were introduced into blastocysts, which were used to
produce chimeric mice. These chimeric mice develop
*Present address: Centro deHemodonacion, Universidad deMurcia, hematological tumors which, despite wide expression
Ronda de Garay, 30003 Murcia, Spain.
of Mll, were only acute leukemias. These results indicate²Present address: Wellcome Trust Immunology Unit, Department
the efficacy of this strategy for creation of mouse modelsof Medicine, University of Cambridge School of Medicine, Cam-
bridge CB2 2SP, United Kingdom. of tumorigenesis mediated via fusion oncogenes.
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Results
Homologous Recombination to Produce
Mll±AF9 Fusion
The strategy of creating fusion genes by homologous
recombination in ES cells was tested by studying the
Mll±AF9 fusion in the development of acute leukemia.
Three different targeting constructs involving the mouse
Mll gene were used (Figure 1). A targeting vector (desig-
nated Mll±AF9; Figure 1A) was prepared in which the
39-terminal human AF9 sequence was fused within exon
8 of Mll, creating a vector in which the AF9 sequence
was fused to Mll at about the position of fusions found
after t(9;11)(p22;q23) in one subset of AF9 breakpoints
(Iida et al., 1993; Nakamura et al., 1993) (Figure 1C com-
pares the junctional sequences with Mll exon 8 and
human AF9 sequences). The targeting clone was made
with the simian virus 40 (SV40) poly(A) site downstream
of the AF9 translation stop codon. A second targeting
vector was prepared with a short peptide epitope (clone
designated Mll±myc; Figure 1B) instead of the AF9 se-
quences. Both vectors also carried the MC1±neomycin
resistance gene (MC1±neo) downstream of the fusion
gene to confer resistance to G418 (Figure 1) and the
herpes simplex virus (HSV) thymidine kinase gene to
allow negative selection of nonhomologous integrations
(Thomas and Capecchi, 1987; Mansour et al., 1988).
Introduction of these targeting vectors into E14 ES
cells allowed selection of clones in which either an AF9
fusion or the peptide fusion had occurred by homolo-
gous recombination at the same position in Mll exon 8
(Figure 1C). Transcription of the fusion gene occurs from
the endogenous Mll promoter, through exon 1 to exon
8 of the gene to include the fused segment. Clones
were injected into blastocysts, and chimeric mice were
produced with varying degrees of chimerism. Two inde-
pendent Mll±AF9 ES cell clones and one Mll±myc ES
cell clone with normal karyotypes were injected into
C57Bl/6 blastocysts.
A third construct was prepared with a fusion involving
exon 3 of Mll (Figures 1D and 1E). This genomic region Figure 1. Mll-Targeting Constructs
was cloned from a l phage library, and a vector was (A) Construction of the Mll±AF9-targeting plasmid. The top map
constructed with a lacZ±SV40 poly(A) cassette (Dear et shows the Mll wild-type allele, indicating the region of exon 8. The
middle map shows the location of the AF9 fusion in Mll exon 8,al., 1995) fused in-frame with Mll exon 3 (Figure 1E).
adjacent to the MC1±neo±poly(A) cassette in the Mll±AF9 targetingThis vector (designated AT±lac) also carried MC1±neo
vector. The HSV thymidine kinase gene (TK) is at the 59 end of theto confer resistance to G418 (Figure 1D; the junctional
vector. The bottom map indicates the organization of the Mll locus
sequences for the targeting vector are shown in Figure in the targeted allele. The restriction fragments corresponding to
1E). A clone with a normal karyotype was injected into wild-type Mll and the targeted Mll±AF9 are 5.5 kb and 4.5 kb EcoRI
C57Bl/6 blastocysts, and chimeric mice were produced. fragments, respectively. The probe used to detect the homologous
recombination events (1.5RXT2) is indicated.
(B) Organization of the Mll±myc targeting vector and that of the
targeted genomic allele. A new 4.1 kb EcoRI fragment is generatedThe Mll-Targeted Alleles Are Active in ES
in the gene after homologous recombination has occurred.Cells and in Chimeric Mice
(C) Comparison of the junctional sequences found in the targeted
The expression of the three Mll fusion genes was as- Mll±AF9 and Mll±myc alleles compared to the mouse Mll exon 8
sessed in ES cells. RNA from three ES cell clones with and the human AF9 sequences. The fusion of the AF9 and MYC tag
the targeted alleles was used for reverse transcription sequences occurs at the BamHI site in exon 8 of Mll.
(D) Map of the AT±lac targeting vector. The positions of Mll exon 3polymerase chain reaction (PCR). (Figure 2A). PCR prim-
(closed box) and the region deleted in the targeted allele (stippleders corresponding to regions of exons 5 and 9 of the
box) are shown in the map of the wild-type allele. The b-galactosi-normal Mll allele facilitated amplification of Mll se-
dase gene with the SV40 poly(A) signal (darkly stippled box in the
quences from all three ES lines (Figure 2A). Specific diagram of the AT±lac targeting vector/allele) was cloned into Mll
inter-exon primers for each of the RNA products ex- exon 3, and the MC1±neo±poly(A) cassette (lightly stippled box) was
pected from the targeted Mll alleles yielded PCR prod- inserted immediately downstream of this. Homologous recombina-
tion of this clone into Mll results in a new 10 kb EcoRI fragmentucts in the ES cell clone with the specific targeted allele
MLL±AF9 Causes Leukemia in Mice
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Figure 2. Expression of the Mll Gene in ES
Cells and in Chimeric Mouse Tissues
(A) ES clones with AT±lac-, Mll±myc-, or Mll±
AF9-targeted alleles were grown for mRNA
isolation. Reverse transcription PCR was car-
ried out on cDNA made from each RNA prep-
aration using primers specific for either en-
dogenous Mll (Mll wild type [wt]), AT±lac,
Mll±myc, or Mll±AF9 cDNA (as indicated).
Products of the PCR reactions were sepa-
rated on 1% agarose and stained with ethid-
ium bromide. Molecular sizes were estimated
by coelectrophoresis of CX174 DNA cut with
HaeIII.
(B) Targeted ES cells were grown on neomy-
cin-resistant embryonic feeders and finally
overnight in their absence. Cells were recov-
ered and attached to microscope slides using
the cytospin centrifuge. The cells were
stained with X-Gal and counterstained with
neutral red. The relevant targeted ES cells are
indicated.
(C) A chimeric mouse derived from injection
of AT±lac ES cells was sacrificed, and cytos-
pin spreads were prepared from hematologi-
cal organs, stained with X-Gal, and counter-
stained with neutral red. Cells staining blue
are present in each of the indicated cytospins
from each organ. BM, bone marrow.
(Figure 2A), showing that mRNA transcripts are made activity, the distribution of ES-derived cells in hemato-
logical tissues. Blue-stained cells were visible in cyto-from the targeted alleles in ES cells. Expression of the
AT±lac allele was substantiated by histochemical analy- spin preparations of bone marrow, spleen, and thymus
cells (Figure 2C). In chimeric bone marrow, megakaryo-sis of b-galactosidase protein production. Cytospin
preparations were made of Mll±AF9, AT±lac, and Mll± cytes, neutrophils, and myelocytes shared nuclear stain-
ing, even though the Mll gene is truncated at exon 3.myc targeted ES cells, and each was stained with X-Gal
to detect b-galactosidase. Blue staining due to This has clear implications for the subcellular location
of the MLL fusion proteins after chromosomal transloca-b-galactosidase enzyme activity was seen in the AT±lac
ES cells, but not in the Mll±AF9 or Mll±myc cells (Figure tions, since these fusions include the corresponding
region of MLL and therefore may be nuclear proteins.2B). Hence, the Mll promoter is active in dividing ES
cells, and the three targeted Mll alleles are correspond- In addition, both the chimeric spleenand thymus contain
blue-stained lymphocytes. Normal mouse bone marrow,ingly expressed in the specific targeted clones.
Chimeric mice were generated with AT±lac targeted spleen, and thymus cells treated in parallel did not ex-
hibit any blue-staining cells (data not shown). Thus, tar-ES cells and used to investigate, via b-galactosidase
geted ES cell derivatives are present in the three major
hematological organs in the AT±lac chimeric mice, and
Mll expression occurs in the ES cell±derived myeloid
(compared with the 13 kb fragment in normal DNA), which was and lymphoid lineage cells in chimeric mice.
detected by the 1.7XhAT13 probe indicated.
(E) The sequence at the junction of Mll exon 3 and the lacZ gene.
The Mll Gene Expression Is WidespreadA previously cloned lacZ cassette with SfiI restriction sites (Dear et
The above evidence suggests a wide distribution of nor-al., 1995) was used to produce an in-frame fusion between Mll and
lacZ genes. mal Mll expression in mice. The targeted AT±lac ES cells
Cell
856
allowed the distribution of Mll promoter activity to be
assessed further during embryogenesis and in adult tis-
sue. Germline transmission of the AT±lac allele was ob-
tained from a number of chimeric mice, and the tissue
distribution of Mll promoter activity was monitored by
the b-galactosidase activity. In parallel with recent data
obtained with a similar lacZ fusion (Yu et al., 1995), we
observed more or less uniform b-galactosidase expres-
sion in embryonic day 13.5 (E13.5) and also in E18.5
heterozygous embryos (data not shown). In addition,
expression continues into adults, where expression of
b-galactosidase was found in most tissues (data not
shown).
The specific cells that express the Mll±lacZ fusion in
the lymphoid organs were assessed by fluorescence-
activated cell sorter (FACS) analysis using a substrate
(CMFDG; see Experimental Procedures) that elicits
green fluorescence in cells containing b-galactosidase
activity. The comparison of single cell suspensions from
the spleen and thymus of AT±lac carrier mice with those
from wild-type mice showed that most of the splenic
and thymic lymphocytes from the 1/2, but not the 1/1,
mice express b-galactosidase activity, and therefore the
Mll promoter is active (Figure 3A).
Since the majority of cells in a normal mouse thymus
express the surface markers CD4 and CD8, the CMFDG
fluorescence data (Figure 3A) indicate that the double-
positive CD41/CD81 T cells express the Mll gene. This
was confirmed using double fluorescence with CMFDG
and antibody binding either CD4 (Figure 3B) or CD8
(Figure 3C). Approximately 93% of thymus cells from a
normal mouse and from an AT±lac 1/2 mouse ex-
pressed CD4 (Figure 3B). The fluorescence profile was
shifted to the right owing to the presence of double-
fluorescent cells expressing both CD4 and b-galactosi-
dase in the AT±lac thymocytes (Figure 3B). Double-
fluorescent cells, positive for the CD8 marker and
b-galactosidase activity, were identified by similar anal-
ysis (Figure 3C). The same proportion of thymocytes
expressed the CD8 marker in both 1/1 and 1/2 ani-
mals, and double-fluorescent cells were present in the
1/2 mouse (Figure 3C).
Splenic B cells (B220 positive) and T cells (B220 nega-
Figure 3. FACS Analysis of b-Galactosidase Expression in Thymustive) from 1/2 mice were subjected to similar analyses
and Spleen Analysis(Figure3D). The 1/1 mouse spleencontains aboutequal
Single cell suspensions were made from spleen and thymus of AT±numbers of B and T cells, as judged by the proportions
lac 1/2 carrier mice or from wild-type 1/1 littermates. Cells wereof B220-positive and B220-negative cells, and the 1/2
stained for internal b-galactosidase, generating green fluorescence,
spleen had approximately similar proportions. In the and for surface antigen with appropriate phycoerythrin-coupled an-
double-fluorescence analysis, both populations of cells tibody. Equivalent quadrants are marked on each profile.
in 1/2 splenocytes show CMFDG staining due to the (A) Spleen and thymus cells were examined with CMFDG fluores-
cence only.presence of b-galactosidase. We conclude that the Mll
(B and C) Thymus populations were examined for double fluores-promoter is active in B cells and T cells.
cence with CMFDG and CD4 (B) or with CMFDG and CD8 (C).
(D) Spleen cells were examined for double fluorescence withMll±AF9 Chimeric Mice Have a High ES
CMFDG and B220.
Cell±Derived Blood Contribution
Cohorts of chimeric mice were generated by injection
any signs of illness were subjected to this analysis (com-of each targeted clone into blastocysts to compare the
pared with samples prepared from either C57 tissue oreffect of the Mll±AF9 fusion gene with the AT±lac and
E14 ES cell extract; Figures 4A±4C).Mll±myc fusions. Peripheral blood samples were taken
Nine chimeric mice, about 9 to 10 months old, derivedfrom adult chimeric mice, and the contribution originat-
by injecting the AT±lac targeted ES cells and with vari-ing from the 129-derived ES cells, injected into the
able chimerism based on estimated coat color contribu-C57Bl/6 blastocysts, was determined by glucose phos-
tion, were examined. Only two of these chimeras hadphate isomerase (GPI) analysis (Papaioannou and John-
son, 1993). Blood samples from groups of mice without any significant E14 contribution in blood (Figure 4A, mice
MLL±AF9 Causes Leukemia in Mice
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Figure 4. GPI Isozyme Analysis of Chimeric Mouse Samples
(A±C) Blood samples were taken from chimeric mice at 6 months of age. GPI analysis was carried out with these samples using starch gel
electrophoresis, in comparison with samples prepared from ES E14 cells and C57Bl/6 blood. Samples from AT±lac (A), Mll±myc (B), and
Mll±AF9 clones F3 and F12 (C) are shown.
(D±G) Samples taken for GPI analysis from blood (PB), bone marrow (BM), and the indicated tissues were analyzed from chimeric mice made
with the AT±lac ES clone (D; AT±lac chimera 1034), an Mll±myc ES clone (E; Mll±myc chimera 1009) or two Mll±AF9 tumor-bearing mice
(Mll±AF9 mouse M4 from clone F3 [F] or Mll±AF9 mouse F1 from clone F12 [G]). PB1 and PB2 refer to blood samples taken at 6 weeks and
at the time of disease occurrence, respectively.
1040 and 1041), and this did not correlate directly with and F12; Figures 5A±5D). Furthermore, three different
groups of chimeras derived at different times from ESthe level of chimerism estimated by coat color. Five
cell clone F3 show a high incidence of acute leukemiaMll±myc chimeras were analyzed at 1 year of age, and
(groups 1±3 in Figures 5A±5C).none showed any ES cell blood contribution (Figure 4B).
The characteristic pathological features of the diseaseConversely, all of the Mll±AF9 mice had a high ES GPI
in the chimeras were an enlarged pale spleen, an en-contribution by about 6 months of age (Figure 4C), irre-
larged pale liver with pronounced white spots, and palespective of coat color. In addition, most of the Mll±AF9
kidneys. The thymi generally appeared normal. The fe-chimeras analyzed had a significant ES cell±derived
murs were macroscopically pale, indicating replace-blood contribution soon after birth (data not shown).
ment of normal hematopoietic tissue by leukemic cells.This high blood contribution was observed for targeted
GPI analysis of tissue specimens from Mll±AF9 mice,ES cells derived from the E14 clones described here
which were sacrificed at the time when symptoms be-and for similar Mll±AF9 targeted ES cells made in the
gan, suggested the existence of a leukemic condition,CCB line (A. Smith, H. I., and T. H. R., unpublished data).
since bone marrow, spleen, and thymus samplesA preferential expansion of ES cell±derived hematopoi-
showed very high ES cell±derived contribution (Figuresetic cells therefore takes place in the Mll±AF9-derived
4F and 4G). An Mll±AF9 chimera M4 (from ES cell clonechimeric mice, but not in AT±lac- or Mll±myc-derived
F3) showed approximately similar ES contribution in
mice.
blood at two separate times of sampling, while at time
of death the bone marrow was essentially all ES-derived
cells (Figure 4F). Mll±AF9 chimera F1 (from ES clone
Mll±AF9 Chimeras Develop Acute Leukemia
F12) showed a progressive increase in ES contribution
Mll±AF9 chimeric mice began to show signs of distress in blood, and both the bone marrow and thymus com-
(from 4 months of age onward) characterized by indolent prised only ES cell derivatives, while the spleen had
habit, slow movement, hunched gait, and ruffled hair, around 90% ES cell derivatives at the time of death
with more advanced disease associated with respiratory (Figure 4G). Contributions of ES-derived cells to other
difficulties. Postmortem examination showed consis- tissues have been tested by GPI analysis in all three
tent evidence of hematologicaldisease, which was char- types of chimeric mice, and all the tissues analyzed
acterized as acute leukemia due to hypercellularity, and were found to have ES cell derivatives (Figures 4D±4G).
blasts accounted for more than 30% of the nucleated However, no tumors of other tissues were found in these
bone marrow cells. Only 3 mice out of a total of 35 mice, despite widespread activity of the Mll promoter
survived beyond 12 months, and the incidence of leuke- (Figures 2 and 3).
mia was approximately the same in chimeras made from While a high proportion of Mll±AF9 mice developed
acute leukemia, no disease appeared in either controltwo independently targeted clones (Mll±AF9 clones F3
Cell
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Figure 5. Incidence of Leukemia in Mll-Tar-
geted Chimeric Mice
Histograms indicating levels of chimerism
(based on coat color) for individual mice and
the age (in months) at which leukemia was
present are shown for each case of Mll±AF9
chimeras (no disease has been found in any
AT±lac or Mll±myc chimeras). Two Mll±AF9
targeted ES clones (F3 and F12) were used
to generate chimeric mice (A±D), and clone
F3 was used for three separate groups of
mice (A±C). One clone of AT±lac and one of
Mll±myc were injected into blastocysts, and
chimeric mice were obtained. The age at
which disease occurred in the Mll±AF9 chi-
meric mice is indicated.
group of AT±lac or Mll±myc mice at 12 months (Figures blasts with cytoplasmic granules staining with Sudan
black B cytochemical stain (the bottom right panel of5E and 5F). This does not appear simply to reflect the
lack of ES cell contribution in these mice, since the level Figure 6A shows a myeloblast whose cytoplasm is
stained by Sudan black).of chimerism, evaluated by coat color, was as high as
90% in some mice (Figure 5). Further GPI analysis of Analysis of tissues from a mouse derived from the
Mll±AF9 ES clone F12 is shown in Figure 6B (mouse F1).tumors from these mice (examples are shown in Figures
4D and 4E) showed that significant numbers of ES cells Femur sections revealed hypercellularity and homoge-
neous appearance of leukemic cells. The liver was highlycontributed to the peripheral organs.
infiltrated with leukemic cells, and these cells stained
using a naphthol AS-D chloroacetate esterase substrateMyeloid Leukemia in the Mll±AF9 Mice
Detailed analysis of the leukemic cells in the chimeric (which is reactive with myeloblastic cells; Figure 6B).
The peripheral blood from this mouse contained cellsMll±AF9 mice established the diagnosis as acute my-
eloid leukemia in those analyzed. All marrow samples with monocytoid appearance (bottom panels of Figure
6B compare blood from F1 with an AT±lac-derived con-analyzed were overtly hypercellular, with a high propor-
tion of blast cells and extramedullary hematopoiesis trol, 1034). This mouse was suffering from an acute my-
eloid leukemia, and the Mll±AF9 mice develop overt,evident in spleen and liver (particularly spleen). In some
mice, circulating red cells containing Howell±Jolly bod- acute leukemia of the myeloid type, showing a range of
differentiation. We cannot however exclude a possibleies were observed (a feature of functional hyposplen-
ism), and a significant percentage of myeloblasts was mixed lineage involvement.
usually evident in the peripheral blood. Some mice ex-
hibited acute leukemia with monocytic differentiation, Discussion
while others showed poorly differentiated blasts in mar-
row and peripheral blood. While an enlarged spleen is Homologous Recombination as a Strategy
to Make Fusion Oncogenesa characteristic of either myeloid or lymphoid acute leu-
kemia, clonal B cell lymphoproliferation was excluded In vivo models of cancer development are needed for a
comprehensive understanding of the biology of cancer.by analysis of immunoglobulin gene rearrangement in
spleen DNA (data not shown). Animal models of tumorigenesis offer an ideal means of
achieving this. The most often used approach is trans-Figure 6 shows specific analysis of the tumor cells
from two Mll±AF9 mice. Histology of liver sections of genesis (Adams and Cory, 1991). More recently, new
technologies based on homologous recombination inmouse M4, compared with a chimeric AT±lac-derived
mouse (1034 in Figure 6A), showed invasion of the M4 ES cells have been used to mimic chromosomal translo-
cations by placing loxP recombination sites on nonho-liver by malignant cells, with heavy tumor deposits
around the blood vessels. Marrow sections revealed mologous chromosomes and selecting for interchromo-
somal translocation (Smith et al., 1995; van Deursen ethypercellularity due to the uniform presence of blast
cells, and the fat spaces typical of normal marrow (seen al., 1995). As an alternative to these approaches, we
have used homologous recombination to generate anin 1034 in Figure 6A) were absent from the femur mar-
row of mouse M4 (Figure 6A). The peripheral blood had in-frame fusion of AF9 with Mll, and we find that this
causes tumors in the chimeric mice. This strategy hasmany circulating myeloblasts, and blood films contained
MLL±AF9 Causes Leukemia in Mice
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Figure 6. Histology of Hematological Tumors
Arising in Mll±AF9 Chimeric Mice
Tissues from Mll±AF9 mice with leukemia
were dissected and fixed in 10% formalin.
AT±lac chimera 1034 was used as a control.
Sections were prepared and stained, as indi-
cated, with hematoxylin and eosin (H&E),
May±GruÈ nwald±Giemsa (MGG), or Sudan
black B, or for naphthol AS-D chloroacetate
esterase.
(A) Comparison of stained tissues from Mll±
AF9 chimera M4 with those from AT±lac chi-
mera 1034.
(B) Comparison of stained tissues from Mll±
AF9 chimera F1 with those from AT±lac chi-
mera 1034.
theadvantage of using the normal transcriptional control be made from our experiments. First, the Mll±AF9 fusion
gene is important for tumor development and, second,elements of Mll to express the Mll±AF9 fusion, much the
same as the MLL±AF9 fusion gene would be controlled the phenotype of those tumors is close to the spectrum
of tumors seen in patients with translocation t(9;11).after the specific chromosomal translocation.
In view of these data, the role of other MLL gene There was no disease development in either the AT±lac
or the Mll±myc chimeric mice, despite the fact that thefusions in tumorigenesis should be readily testable by
using a similar strategy to clone MLL fusions with, for site of fusion of the MYC peptide epitope was identical
with that of the AF9 fusion. Also, chimeric mice estab-example, AF4 or ENL (corresponding to t[4;11] and
t[11;19], respectively). Their effect on hematological de- lished with cells carrying the Mll±AF9 fusion gene only
developed hematological tumors, even though the usevelopment and tumor phenotype could be assessed. In
addition, it is likely that a similar methodology could of the AT±lac targeted fusion allowed the demonstration
of Mll promoter activity in a wide variety of locationsbe applied to other gene fusions commonly found in
hematological tumors, e.g., the BCR±ABL gene in my- during mouse development and in adult tissues (Figures
2 and 3).elogenous leukemia or fusions in solid tumors, such as
the sarcomas, which also have consistent chromosomal Our results provide formal proof that Mll±AF9 is impor-
tant for hematological malignancy and, by creating atranslocations (Rabbitts, 1994).
recapitulation of the effect of chromosomal transloca-
tion, provide formal proof that chromosomal transloca-The Mll±AF9 Fusion Gene Causes Acute Leukemia
The MLL gene on human chromosome 11, band q23, is tions are important in tumor development. Understand-
ing the role of AF9 in derivation of the tumor type willinvolved with a remarkably large number of chromo-
somal translocations and inversions (reviewed by Ber- necessitate a number of other comparisons, for example
with the effect of MLL±AF4. However, it is very importantnard and Berger, 1995), and the site of breakage is rather
consistent on the derivative 11q chromosome, which is to note that the Mll±AF9 fusion gene discussed here is
present, and presumably expressed, in hematopoieticconsidered important for tumor development (Rowley,
1992). Various fusion partners can be linked to the MLL stem cells. Thus, the specificity of tumors from the my-
eloid lineage suggests that the MLL±AF9 fusion proteingene after the formation of abnormal chromosomes
(Bernard and Berger, 1995), but the role of the incoming is predominantly oncogenic in myeloid or myeloid-com-
mitted cells. It is therefore conceivable that MLL translo-fusion partner is not clear at present.
A number of conclusions about the MLL fusions can cations could occur in other hematopoietic cells that
Cell
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thereby generated were estimated by agouti coat color comparedremain normal. Nonetheless, lymphoid tumors are
with the black color of the recipient strain.known in humans that carry t(9;11) and thus the MLL±
AF9 fusion. In view of our data, it is difficult to explain
Mouse Analysis
such tumors unless the incidence of lymphoid tumors GPI enzyme isozyme analysis was performed on blood or tissue
is low in the chimeric mice and would only be detected samples as described previously (Papaioannou and Johnson, 1993).
in a very large cohort of chimeric mice. Further, the Cytospins of ES cells or single cell suspensions of bone marrow,
spleen, or thymus from chimeric mice were prepared and fixed insituation may be influenced by the genetic background
2% formaldehyde prior to staining with X-Gal. Analysis of b-gal-of the mice. In humans, the timing of theMLL-associated
actosidase activity in cells derived from thymus and spleen waschromosomal translocation and the precise stage of
carried using 4-chloromethyl-fluorescein di-b-D-galactopyranoside
commitment of the cell in which the translocation occurs (CMFDG) as recommended by the manufacturer (Molecular Probes).
may combine to determine lineage of the tumor. Single cell suspensions in PBS containing 2% fetal calf serum were
In view of the long latency of tumor development in loaded with CMFDG after hypotonic shock for 2 min by addition of
0.2 mM CMFDG in water. The surface markers B220, CD3, CD4,the Mll±AF9 chimeric mice, it seems probable that sec-
and CD8 were detected using antibodies directly coupled to phy-ondary mutations in other oncogenes are necessary for
coerythrin (Pharmingen).overt tumor development. The two-hit model of MLL-
mediated tumorigenesis (Yu et al., 1995) incorporates Acknowledgments
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